ALSEMPHARMA
ActiveSummary
The computed 12-month bankruptcy probability of ALSEMPHARMA is 4.0% (moderate). The 2025 annual accounts show negative equity (-€66,946) and a net result of -€47,740. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 8% of 4,978 sector peers (NACE 47, financial year 2025). The company has been active since 1997 and the Belgian Official Gazette contains no insolvency or warning signals.
Directors
Owners and capital
Owners
2 ownersChain of control
- HUNTSOLEM
- ALSEMPHARMA
Highest known parent: HUNTSOLEM. The sources do not say who stands above it.
Owners 2
- HUNTSOLEMparentSourceaccounts HUNTSOLEM 2025100%
- TWEE-DEparent99%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.